Back to results
US 2026/0055428 A1Published application
Modified virus-like particles of cmv
AssigneeSaiba Animal Health AG
InventorsAndris ZELTINS, Kaspars TARS
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeSaiba Animal Health AG
InventorsAndris ZELTINS, Kaspars TARS
Estimating the term…
The present invention relates to a modified virus-like particle (VLP) of cucumber mosaic virus (CMV) comprising at least one chimeric CMV polypeptide, wherein said at least one chimeric CMV polypeptide comprises, preferably consists of (i) a CMV polypeptide, wherein said CMV polypeptide comprises a coat protein of CMV or an amino acid sequence having a sequence identity of at least 75% with SEQ ID NO:48; and (ii) a polypeptide comprising, preferably consisting of, a stretch of consecutive negative amino acids, wherein said negative amino acids are independently selected from aspartic acid or glutamic acid, wherein said polypeptide is inserted between any amino acid residue of said CMV polypeptide corresponding to any amino acid residue between position 75 and position 85 of SEQ ID NO:48, as well as to compositions and pharmaceutical compositions comprising such modified VLPs to which antigens are linked, which compositions preferably serve as vaccine platform for generating immune responses, in particular antibody responses, against said antigens linked to the modified CMV VLPs.
A modified virus-like particle (VLP) of cucumber mosaic virus (CMV) comprising at least one chimeric CMV polypeptide, wherein said at least one chimeric CMV polypeptide comprises, preferably consists of
The modified VLP of CMV of any one of the preceding claims, wherein said CMV polypeptide is a coat protein of CMV or an amino acid sequence having a sequence identity of at least 90%, preferably 95% with SEQ ID NO:48.
The modified VLP of CMV of any one of the preceding claims, wherein said CMV polypeptide comprises, preferably consists of, the amino acid sequence of SEQ ID NO:5, wherein said polypeptide comprising said stretch of consecutive negative amino acids is inserted between amino acid residues of position 88 and position 89 of said SEQ ID NO:5.
The modified VLP of CMV of any one of the preceding claims, wherein said stretch of consecutive negative amino acids has a length of 3 to 10 amino acids.
The modified VLP of CMV of any one of the preceding claims, wherein said stretch of consecutive negative amino acids consists solely of glutamic acids.
The modified VLP of CMV of any one of the preceding claims, wherein said polypeptide comprising said stretch of consecutive negative amino acids further comprises a first amino acid linker and a second amino acid linker, wherein said first amino acid linker is positioned at the N-terminus of said stretch of consecutive negative amino acids, and said second amino acid linker is positioned at the C-terminus of said stretch of consecutive negative amino acids, and wherein said first and said second amino acid linker is independently selected from the group consisting of:
The modified VLP of CMV of any one of the preceding claims, wherein said polypeptide comprises, preferably consists of, SEQ ID NO:62, SEQ ID NO:63 or SEQ ID NO:64.
Dependencies are inferred from the claim text.